Combining patritumab with EGFR TKIs may be beneficial in treating HRG-overexpressing NSCLC patients with resistance to EGFR inhibitors, as it can overcome HRG-dependent EGFR inhibitor resistance[66]. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.